To validate the expression pattern of WBP2 in wild-type glioma, we excluded the 20 specimens with IDH1/2 mutation and found that WBP2 was highly expressed in 78.2% of wild-type glioma samples (43/55), in which 36 samples defined as grade III glioma presented high WBP2 expression (Table 1). Here, IDH1 is linked to central nervous system cancer.